These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 31424273)

  • 1. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
    Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
    Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    Kulke MH; Benson AB; Dasari A; Huynh L; Cai B; Totev T; Roesner N; Duh MS; Neary MP; Maurer VE; Shih BE; Dagohoy CG; Chan J; Bergsland EK
    Oncologist; 2019 Aug; 24(8):1056-1065. PubMed ID: 30606883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.
    Bellizzi AM
    Surg Oncol Clin N Am; 2020 Apr; 29(2):185-208. PubMed ID: 32151355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
    Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.
    Kahraman S; Bardakci M; Aykan MB; Yasar S; Erol C; Hizal M; Akinci MB; Kos FT; Kos T; Dede DS; Karadurmus N; Yalcin S; Sendur MAN; Yalcin B
    J Cancer Res Ther; 2023; 19(2):347-354. PubMed ID: 37006071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Functional Pancreatic Neuroendocrine Neoplasms.
    Magi L; Marasco M; Rinzivillo M; Faggiano A; Panzuto F
    Curr Treat Options Oncol; 2023 Jul; 24(7):725-741. PubMed ID: 37103745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.
    Ikeda M; Hijioka S; Ito T; Matsumoto S; Honma Y; Ueno M; Okano N; Aoki T; Furuse J
    Jpn J Clin Oncol; 2024 Aug; 54(8):880-886. PubMed ID: 38677983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AJCC Cancer Staging System Version 9: Practice-Informing Updates for Gastroenteropancreatic Neuroendocrine Tumors.
    Chan K; Chauhan A; Shi C
    Ann Surg Oncol; 2024 Aug; 31(8):4834-4836. PubMed ID: 38869764
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.
    Chen YY; Guo WJ; Shi YF; Su F; Yu FH; Chen RA; Wang C; Liu JX; Luo J; Tan HY
    BMC Gastroenterol; 2023 Dec; 23(1):440. PubMed ID: 38097952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
    Giri S; Sahoo J
    World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort.
    Panzuto F; Andrini E; Lamberti G; Pusceddu S; Rinzivillo M; Gelsomino F; Raimondi A; Bongiovanni A; Davì MV; Cives M; Brizzi MP; Persano I; Zatelli MC; Puliafito I; Tafuto S; Campana D
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610840
    [No Abstract]   [Full Text] [Related]  

  • 15. A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.
    De Divitiis C; von Arx C; Carbone R; Tatangelo F; Di Girolamo E; Romano GM; Ottaiano A; de Lutio di Castelguidone E; Iaffaioli RV; Tafuto S
    Onco Targets Ther; 2015; 8():669-75. PubMed ID: 25878507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal side effects of somatostatin analogs in neuroendocrine tumors: a focused review.
    Marasco M; Dell'Unto E; Laviano A; Campana D; Panzuto F
    J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38783558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory carcinoid syndrome: a review of treatment options.
    Riechelmann RP; Pereira AA; Rego JF; Costa FP
    Ther Adv Med Oncol; 2017 Feb; 9(2):127-137. PubMed ID: 28203303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.
    Cuyle PJ; Prenen H
    Ann Gastroenterol; 2018; 31(2):140-150. PubMed ID: 29507461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-cirrhotic hyperammonaemic encephalopathy secondary to metastatic pancreatic neuroendocrine tumour treated with peptide receptor radio nucleotide therapy and transarterial chemoembolisation.
    Holmes Z; Beasley H; Naidoo M; Michael M
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171636
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.